EXEL - Rasio utang marang kapitalisasi buku Exelixis, Inc.

Effective management at Exelixis, Inc. (EXEL) ensures high profitability by protecting Cabometyx patents. The current leverage ratio on balance sheet capital demonstrates financial stability, with the level sitting around 0.08. However, the development of targeted therapy requires colossal expenditures and strict government oversight. Business stability is supported by diversified raw material supply chains between Europe and the US.

EXEL Exelixis, Inc.: Rasio utang marang kapitalisasi buku ing interval 04.07.2022 - 27.10.2026

Ringkesan rincian data analitis Exelixis Inc (EXEL)

- rega lan prakiraan konsensus rega:

Rega saham Exelixis, Inc.|EXEL - Target konsensus

- data kapitalisasi pasar:

Nilai pasar Exelixis Inc.|EXEL - Total Nilai Perusahaan

- data kapitalisasi buku:

Aset Bersih saben Siji Saham Exelixis|EXEL - Nilai Buku Perusahaan|Rasio Nilai Pasar marang Nilai Buku exelixis.com|EXEL - Aset Perusahaan

- data utang lan likuiditas:

Total Utang marang Modal Exelixis, Inc.|EXEL - Tanggungan utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas Exelixis Corp|EXEL - Utang kumulatif perusahaan|Utang marang nilai buku Exelixis Inc.

Analisis kabeh metrik perusahaan:EXEL, Exelixis, Inc.

Fundamental selection of high-quality assets is based on solvency analysis via the total liabilities-to-equity ratio. This coefficient measures the business's reliance on borrowed funds, which is critical for Exelixis, Inc. (EXEL) when scaling therapy within the growing oncology segment; therefore, the current debt level relative to balance sheet equity serves as an indicator of financial resilience to market shocks.

Pesaing Exelixis, Inc. (EXEL)